Asterias Biotherapeutics Shares Up 15.6% Premarket After Independent Data Monitoring Committee Completed Last Intermediate Review Of AST-OPC1 Clinical Trial In Acute Spinal Cord Injury And Recommended Continuation Of Study Without Modification
Benzinga Newsdesk